Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656469 · ClinicalTrials.gov registry record · NA
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
A NA study of Anxiety Disorders and Mood Disorders, sponsored by Maastricht University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
- 9
- Study locations
NCT05656469: Recruiting NA study of Anxiety Disorders and Mood Disorders, sponsored by Maastricht University Medical Center.
NCT05656469 is a NA study of Anxiety Disorders and Mood Disorders that is actively recruiting participants, run by Maastricht University Medical Center. The registered enrollment target is 2,500 participants, above the 1,110-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (125% higher). The trial reports 9 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05656469, a NA study of Anxiety Disorders and Mood Disorders, is actively recruiting participants, sponsored by Maastricht University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
- 9
- Study locations
Study Summary
A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.
Primary Outcome
A standardised self-report tool that measures mental health recovery as defined by the client. Repeated use of the instrument makes it possible to detect change over time. Score range 38-152. Higher scores mean a better outcome.
Conditions Studied
Interventions
- OTHER Personalised medication advice based on pharmacogenetic testing
Study Locations (9)
Other
- University Hospital Bonn, Department of Psychiatry and Psychotherapy - Bonn
- Ludwig-Maximilian University, University Hospital, Institute of Psychiatric Phenomics and Genomics (IPPG) - München
- Parnassia Psychiatric Institute, Department of Psychiatry - Amsterdam
- Maastricht University, Department of Psychiatry and Neuropsychology - Maastricht
- Babeş-Bolyai University, Department of Clinical Psychology and Psychotherapy - Cluj-Napoca
- University of Belgrade, Faculty of Pharmacy - Belgrade
- Fundació Clínic per a la Recerca Biomèdica, Department of Psychiatry and Psychology, Hospital Clínic - Barcelona
- King's College, Institute of Psychiatry, Psychology & Neuroscience - London
New York
- SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05656469 shows while recruiting
NCT05656469 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,110-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (125% higher).
The record links to 3 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention - of which Personalised medication advice based on pharmacogenetic testing is the first listed.
NCT05656469 lists 9 locations in 2 states (Other, New York).
Frequently Asked Questions
What is clinical trial NCT05656469 about?
NCT05656469 is a clinical study titled "Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders". A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders...
What is the current status of trial NCT05656469?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2023-02-23. Estimated completion is 2026-09.
What conditions does trial NCT05656469 study?
This clinical trial studies the following conditions: Anxiety Disorders, Mood Disorders, Psychotic Disorders.
What interventions are being tested in trial NCT05656469?
The interventions under investigation include: Personalised medication advice based on pharmacogenetic testing (OTHER).
Who is sponsoring clinical trial NCT05656469?
This trial is sponsored by Maastricht University Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05656469 being conducted?
This trial has 9 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05656469's enrollment target sits among peer trials
2,500 5th of 84 higher than 80 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
RECRUITING · NA
-
Managing Anxiety in Pediatric Primary Care (MAPP)
RECRUITING · NA
-
DINO RCT - Treating Anxiety in Children With Autism
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI